Home » Stocks » Correvio Pharma

Correvio Pharma Corp. (CORV)

May 26, 2020 - CORV was delisted after being acquired by CXRXF
Stock Price: $0.420 USD 0.000 (0.00%)
Updated Jun 5, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 27.79M
Revenue (ttm) 32.63M
Net Income (ttm) -35.18M
Shares Out 66.19M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jun 5, 2020
Last Price $0.420
Previous Close $0.420
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.416 - 0.420
Day's Volume 0
52-Week Range 0.210 - 2.790

More Stats

Market Cap 27.79M
Enterprise Value 59.75M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 66.19M
Float 23.24M
EPS (basic) -0.79
EPS (diluted) -0.80
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.31M
Short Ratio 0.78
Short % of Float 9.96%
Beta 0.22
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.85
PB Ratio 10.46
Revenue 32.63M
Operating Income -27.45M
Net Income -35.18M
Free Cash Flow -27.20M
Net Cash -31.96M
Net Cash / Share -0.48
Gross Margin 69.89%
Operating Margin -84.12%
Profit Margin -107.80%
FCF Margin -83.36%
ROA -28.95%
ROE -1,158.13%
ROIC -64.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0
What these ratings mean

Analyst Consensus: Hold

Price Target

$0.42*
Low
0.42
Current: $0.420
High
0.42
Target: 0.42
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow
Year2019201820172016201520142013201220112010
Revenue32.6328.6724.0125.2620.9130.044.510.791.5166.06
Revenue Growth13.81%19.44%-4.94%20.78%-30.4%565.97%471.74%-47.57%-97.72%-
Gross Profit22.8120.3817.2318.9514.3220.023.580.791.5166.06
Operating Income-27.45-26.34-22.98-14.55-22.08-16.59-16.70-25.96-26.4636.67
Net Income-35.18-16.58-29.81-19.62-24.46-18.234.77-18.32-27.9235.50
Shares Outstanding44.2835.1533.1925.2618.2016.2312.7712.2512.2312.16
Earnings Per Share-0.79-0.47-0.90-0.79-1.34-1.120.37-1.49-2.302.90
Operating Cash Flow-27.08-25.78-24.82-15.89-16.27-18.53-16.77-24.94-27.612.68
Capital Expenditures-0.13-0.28-0.01-0.01-0.13-0.52-0.04-0.14-0.68-0.27
Free Cash Flow-27.20-26.06-24.83-15.90-16.40-19.05-16.81-25.08-28.292.40
Cash & Equivalents15.2417.5724.1829.3119.8615.0313.3141.2748.6476.89
Total Debt47.2041.5240.0019.399.6012.00-32.5025.0025.00
Net Cash / Debt-31.96-23.95-15.829.9110.263.0313.318.7723.6451.89
Assets58.8959.6466.8167.0648.2350.1247.3344.7954.0482.32
Liabilities59.7352.7350.6233.0328.2932.9824.6936.9328.7531.41
Book Value-0.836.9116.1934.0219.9417.1422.647.8625.2950.92
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Correvio Pharma Corp.
Country Canada
Employees 133

Stock Information

Ticker Symbol CORV
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: CORV

Description

Correvio Pharma, a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its products comprise Aggrastat (tirofiban hydrochloride), (an intravenous anti-platelet drug for patients with acute coronary syndrome; and Brinavess (vernakalant IV), a novel, atrial-preferential antiarrhythmic agent for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.